Bolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs

Retrieved on: 2022-03-09 03:58:00

Tags for this article:

Clinical medicine

Medicine

Branches of biology

Cancer immunotherapy

Immune system

Clusters of differentiation

Tumor microenvironment

PD-L1

Immunotherapy

Tumor-associated macrophage

Checkpoint inhibitor

Bolt Biotherapeutics, Inc.

Click the tags to see associated articles and topics

Bolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs. View article details on HISWAI: https://www.bakersfield.com/ap/news/bolt-biotherapeutics-to-present-updates-for-three-preclinical-immuno-oncology-pipeline-programs/article_8217a1ef-1c97-5bf2-990c-862afa7309e0.html

Excerpt

Bolt Bio's proprietary Boltbody™ Immune-stimulating Antibody ... (ISACs) are designed to target tumor cells for elimination by the immune system.

Article found on: www.bakersfield.com

View Original Article